- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
According to our latest study, the global Tyrosine Kinase JAK Inhibitors market size was valued at USD 31360 million in 2022 and is forecast to a readjusted size of USD 497670 million by 2029 with a CAGR of 48.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
Market competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42% market sharers.
This report is a detailed and comprehensive analysis for global Tyrosine Kinase JAK Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Tyrosine Kinase JAK Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Tyrosine Kinase JAK Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Tyrosine Kinase JAK Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Tyrosine Kinase JAK Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tyrosine Kinase JAK Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tyrosine Kinase JAK Inhibitors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Incyte, Novartis, Eli Lilly and Gilead, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Tyrosine Kinase JAK Inhibitors market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Tofacitinib
Ruxolitinib
Baricitinib
Market segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
Major players covered
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tyrosine Kinase JAK Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tyrosine Kinase JAK Inhibitors, with price, sales, revenue and global market share of Tyrosine Kinase JAK Inhibitors from 2018 to 2023.
Chapter 3, the Tyrosine Kinase JAK Inhibitors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tyrosine Kinase JAK Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Tyrosine Kinase JAK Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tyrosine Kinase JAK Inhibitors.
Chapter 14 and 15, to describe Tyrosine Kinase JAK Inhibitors sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Tyrosine Kinase JAK Inhibitors
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Tofacitinib
1.3.3 Ruxolitinib
1.3.4 Baricitinib
1.4 Market Analysis by Application
1.4.1 Overview: Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Rheumatoid Arthritis (RA)
1.4.3 Polycythemia Vera (PCV)
1.4.4 Myelofibrosis (MF)
1.4.5 Others
1.5 Global Tyrosine Kinase JAK Inhibitors Market Size & Forecast
1.5.1 Global Tyrosine Kinase JAK Inhibitors Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Tyrosine Kinase JAK Inhibitors Sales Quantity (2018-2029)
1.5.3 Global Tyrosine Kinase JAK Inhibitors Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Product and Services
2.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Incyte
2.2.1 Incyte Details
2.2.2 Incyte Major Business
2.2.3 Incyte Tyrosine Kinase JAK Inhibitors Product and Services
2.2.4 Incyte Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Incyte Recent Developments/Updates
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Tyrosine Kinase JAK Inhibitors Product and Services
2.3.4 Novartis Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis Recent Developments/Updates
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business
2.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Product and Services
2.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Eli Lilly Recent Developments/Updates
2.5 Gilead
2.5.1 Gilead Details
2.5.2 Gilead Major Business
2.5.3 Gilead Tyrosine Kinase JAK Inhibitors Product and Services
2.5.4 Gilead Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Gilead Recent Developments/Updates
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Product and Services
2.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sanofi Recent Developments/Updates
2.7 Galapagos
2.7.1 Galapagos Details
2.7.2 Galapagos Major Business
2.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Product and Services
2.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Galapagos Recent Developments/Updates
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Product and Services
2.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 AbbVie Recent Developments/Updates
2.9 Vertex
2.9.1 Vertex Details
2.9.2 Vertex Major Business
2.9.3 Vertex Tyrosine Kinase JAK Inhibitors Product and Services
2.9.4 Vertex Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Vertex Recent Developments/Updates
2.10 Teva
2.10.1 Teva Details
2.10.2 Teva Major Business
2.10.3 Teva Tyrosine Kinase JAK Inhibitors Product and Services
2.10.4 Teva Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Teva Recent Developments/Updates
2.11 Astellas Pharma
2.11.1 Astellas Pharma Details
2.11.2 Astellas Pharma Major Business
2.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product and Services
2.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Astellas Pharma Recent Developments/Updates
2.12 Celgene
2.12.1 Celgene Details
2.12.2 Celgene Major Business
2.12.3 Celgene Tyrosine Kinase JAK Inhibitors Product and Services
2.12.4 Celgene Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Celgene Recent Developments/Updates
2.13 CTI BioPharma
2.13.1 CTI BioPharma Details
2.13.2 CTI BioPharma Major Business
2.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product and Services
2.13.4 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 CTI BioPharma Recent Developments/Updates
3 Competitive Environment: Tyrosine Kinase JAK Inhibitors by Manufacturer
3.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Manufacturer (2018-2023)
3.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer (2018-2023)
3.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Tyrosine Kinase JAK Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Tyrosine Kinase JAK Inhibitors Manufacturer Market Share in 2022
3.4.2 Top 6 Tyrosine Kinase JAK Inhibitors Manufacturer Market Share in 2022
3.5 Tyrosine Kinase JAK Inhibitors Market: Overall Company Footprint Analysis
3.5.1 Tyrosine Kinase JAK Inhibitors Market: Region Footprint
3.5.2 Tyrosine Kinase JAK Inhibitors Market: Company Product Type Footprint
3.5.3 Tyrosine Kinase JAK Inhibitors Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Tyrosine Kinase JAK Inhibitors Market Size by Region
4.1.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2018-2029)
4.1.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2018-2029)
4.1.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2018-2029)
4.2 North America Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029)
4.3 Europe Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029)
4.4 Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029)
4.5 South America Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029)
4.6 Middle East and Africa Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2029)
5.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2018-2029)
5.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2029)
6.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2018-2029)
6.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2018-2029)
7 North America
7.1 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2029)
7.2 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2029)
7.3 North America Tyrosine Kinase JAK Inhibitors Market Size by Country
7.3.1 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2029)
7.3.2 North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2029)
8.2 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2029)
8.3 Europe Tyrosine Kinase JAK Inhibitors Market Size by Country
8.3.1 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2029)
8.3.2 Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Tyrosine Kinase JAK Inhibitors Market Size by Region
9.3.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2029)
10.2 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2029)
10.3 South America Tyrosine Kinase JAK Inhibitors Market Size by Country
10.3.1 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2029)
10.3.2 South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Tyrosine Kinase JAK Inhibitors Market Size by Country
11.3.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Tyrosine Kinase JAK Inhibitors Market Drivers
12.2 Tyrosine Kinase JAK Inhibitors Market Restraints
12.3 Tyrosine Kinase JAK Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Tyrosine Kinase JAK Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tyrosine Kinase JAK Inhibitors
13.3 Tyrosine Kinase JAK Inhibitors Production Process
13.4 Tyrosine Kinase JAK Inhibitors Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tyrosine Kinase JAK Inhibitors Typical Distributors
14.3 Tyrosine Kinase JAK Inhibitors Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Tyrosine Kinase JAK Inhibitors Product and Services
Table 6. Pfizer Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Recent Developments/Updates
Table 8. Incyte Basic Information, Manufacturing Base and Competitors
Table 9. Incyte Major Business
Table 10. Incyte Tyrosine Kinase JAK Inhibitors Product and Services
Table 11. Incyte Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Incyte Recent Developments/Updates
Table 13. Novartis Basic Information, Manufacturing Base and Competitors
Table 14. Novartis Major Business
Table 15. Novartis Tyrosine Kinase JAK Inhibitors Product and Services
Table 16. Novartis Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Novartis Recent Developments/Updates
Table 18. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 19. Eli Lilly Major Business
Table 20. Eli Lilly Tyrosine Kinase JAK Inhibitors Product and Services
Table 21. Eli Lilly Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Eli Lilly Recent Developments/Updates
Table 23. Gilead Basic Information, Manufacturing Base and Competitors
Table 24. Gilead Major Business
Table 25. Gilead Tyrosine Kinase JAK Inhibitors Product and Services
Table 26. Gilead Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Gilead Recent Developments/Updates
Table 28. Sanofi Basic Information, Manufacturing Base and Competitors
Table 29. Sanofi Major Business
Table 30. Sanofi Tyrosine Kinase JAK Inhibitors Product and Services
Table 31. Sanofi Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Sanofi Recent Developments/Updates
Table 33. Galapagos Basic Information, Manufacturing Base and Competitors
Table 34. Galapagos Major Business
Table 35. Galapagos Tyrosine Kinase JAK Inhibitors Product and Services
Table 36. Galapagos Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Galapagos Recent Developments/Updates
Table 38. AbbVie Basic Information, Manufacturing Base and Competitors
Table 39. AbbVie Major Business
Table 40. AbbVie Tyrosine Kinase JAK Inhibitors Product and Services
Table 41. AbbVie Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. AbbVie Recent Developments/Updates
Table 43. Vertex Basic Information, Manufacturing Base and Competitors
Table 44. Vertex Major Business
Table 45. Vertex Tyrosine Kinase JAK Inhibitors Product and Services
Table 46. Vertex Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Vertex Recent Developments/Updates
Table 48. Teva Basic Information, Manufacturing Base and Competitors
Table 49. Teva Major Business
Table 50. Teva Tyrosine Kinase JAK Inhibitors Product and Services
Table 51. Teva Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Teva Recent Developments/Updates
Table 53. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 54. Astellas Pharma Major Business
Table 55. Astellas Pharma Tyrosine Kinase JAK Inhibitors Product and Services
Table 56. Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Astellas Pharma Recent Developments/Updates
Table 58. Celgene Basic Information, Manufacturing Base and Competitors
Table 59. Celgene Major Business
Table 60. Celgene Tyrosine Kinase JAK Inhibitors Product and Services
Table 61. Celgene Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Celgene Recent Developments/Updates
Table 63. CTI BioPharma Basic Information, Manufacturing Base and Competitors
Table 64. CTI BioPharma Major Business
Table 65. CTI BioPharma Tyrosine Kinase JAK Inhibitors Product and Services
Table 66. CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. CTI BioPharma Recent Developments/Updates
Table 68. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 69. Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer (2018-2023) & (USD Million)
Table 70. Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 71. Market Position of Manufacturers in Tyrosine Kinase JAK Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 72. Head Office and Tyrosine Kinase JAK Inhibitors Production Site of Key Manufacturer
Table 73. Tyrosine Kinase JAK Inhibitors Market: Company Product Type Footprint
Table 74. Tyrosine Kinase JAK Inhibitors Market: Company Product Application Footprint
Table 75. Tyrosine Kinase JAK Inhibitors New Market Entrants and Barriers to Market Entry
Table 76. Tyrosine Kinase JAK Inhibitors Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 78. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 79. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 80. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 81. Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2018-2023) & (USD/Unit)
Table 82. Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2024-2029) & (USD/Unit)
Table 83. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 84. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 85. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2018-2023) & (USD Million)
Table 86. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2024-2029) & (USD Million)
Table 87. Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2018-2023) & (USD/Unit)
Table 88. Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2024-2029) & (USD/Unit)
Table 89. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 90. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 91. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2018-2023) & (USD Million)
Table 92. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2024-2029) & (USD Million)
Table 93. Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2018-2023) & (USD/Unit)
Table 94. Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2024-2029) & (USD/Unit)
Table 95. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 96. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 97. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 98. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 99. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 100. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 101. North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 102. North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 103. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 104. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 105. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 106. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 107. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 108. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 109. Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 112. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 113. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 114. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 115. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 116. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 117. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 118. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 119. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 120. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 121. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 122. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 123. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2018-2023) & (K Units)
Table 124. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2024-2029) & (K Units)
Table 125. South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 126. South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 127. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2018-2023) & (K Units)
Table 128. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2024-2029) & (K Units)
Table 129. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2018-2023) & (K Units)
Table 130. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2024-2029) & (K Units)
Table 131. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2018-2023) & (K Units)
Table 132. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2024-2029) & (K Units)
Table 133. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 134. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 135. Tyrosine Kinase JAK Inhibitors Raw Material
Table 136. Key Manufacturers of Tyrosine Kinase JAK Inhibitors Raw Materials
Table 137. Tyrosine Kinase JAK Inhibitors Typical Distributors
Table 138. Tyrosine Kinase JAK Inhibitors Typical Customers
List of Figures
Figure 1. Tyrosine Kinase JAK Inhibitors Picture
Figure 2. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Type in 2022
Figure 4. Tofacitinib Examples
Figure 5. Ruxolitinib Examples
Figure 6. Baricitinib Examples
Figure 7. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Application in 2022
Figure 9. Rheumatoid Arthritis (RA) Examples
Figure 10. Polycythemia Vera (PCV) Examples
Figure 11. Myelofibrosis (MF) Examples
Figure 12. Others Examples
Figure 13. Global Tyrosine Kinase JAK Inhibitors Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Tyrosine Kinase JAK Inhibitors Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Tyrosine Kinase JAK Inhibitors Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Tyrosine Kinase JAK Inhibitors Average Price (2018-2029) & (USD/Unit)
Figure 17. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Tyrosine Kinase JAK Inhibitors by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Tyrosine Kinase JAK Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Tyrosine Kinase JAK Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2018-2029) & (USD/Unit)
Figure 32. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2018-2029) & (USD/Unit)
Figure 35. North America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 55. China Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Tyrosine Kinase JAK Inhibitors Market Drivers
Figure 76. Tyrosine Kinase JAK Inhibitors Market Restraints
Figure 77. Tyrosine Kinase JAK Inhibitors Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Tyrosine Kinase JAK Inhibitors in 2022
Figure 80. Manufacturing Process Analysis of Tyrosine Kinase JAK Inhibitors
Figure 81. Tyrosine Kinase JAK Inhibitors Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
